
Artrya (ASX: AYA) is consolidating after a strong rally as investors assess its U.S. expansion, FDA progress, and commercial rollout of the AI-powered Salix platform. Despite the pullback, growing adoption and clinical milestones continue to support its long-term growth outlook.